Predicta Biosciences

Predicta Biosciences has launched its first commercial diagnostic product—GenoPredicta—for molecular diagnosis of multiple myeloma using whole genome sequencing on bone marrow or blood samples. The test provides comprehensive genomic data to guide prognosis and treatment selection, including predicting response to advanced immunotherapies like CAR-T cell therapy. Early results show the ability to replace invasive biopsies with simple blood draws while providing more actionable information than traditional FISH assays. Therapeutic programs are at the target identification/discovery stage using their growing multiomic patient database.